First Affirmative Financial Network raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 28.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 288 shares of the biopharmaceutical company’s stock after buying an additional 64 shares during the quarter. First Affirmative Financial Network’s holdings in Regeneron Pharmaceuticals were worth $205,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the company. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $49,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Trading Down 0.6 %
NASDAQ:REGN opened at $683.08 on Friday. The firm has a market capitalization of $75.06 billion, a P/E ratio of 16.90, a P/E/G ratio of 1.62 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $723.36 and a 200 day moving average of $928.61. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20.
Analyst Upgrades and Downgrades
View Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- What Are Dividend Contenders? Investing in Dividend Contenders
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Investing in the High PE Growth Stocks
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- 3 Grocery Stocks That Are Proving They Are Still Essential
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.